Archives

by in
Entry Author Date Location
Keryx Finally Succeeds With a Clinical Trial, for Kidney Disease Drug 01/28/13 New York
Biogen ALS Failure Highlights Clinical Trial Frustrations 01/10/13 Boston
Biogen Idec’s ALS Drug Fails Phase III Trial 01/03/13 Boston
Xconomy Boston’s Top 20 Stories of the Year: Editor’s Picks 12/26/12 Boston
Xconomist of the Week: Alexis Borisy Still Likes Early Stage Biotechs 12/20/12 Boston
Ultragenyx Pharmaceutical Obtains $75,000,000 Series B Round 12/20/12 San Francisco
East Coast Life Sciences Roundup: Selecta, Rib-X, Cambridge, & More 11/30/12 Boston
Rib-X Closes First Tranche of $67.5 Million Preferred Stock Financing 11/29/12 Boston
Selecta in Development Deal with Sanofi Worth up to $900 Million 11/28/12 Boston
East Coast Life Sciences Roundup: Insider Trading, Shire, Pfizer 11/23/12 Boston
Celgene, Sanofi, Stryker Execs Charged With Insider Trading 11/19/12 New York
Janssen Forms “Investigator Databank” to Help Streamline Drug Trials 11/15/12 San Diego
San Diego’s Regulus Therapeutics Readies for IPO This Week 10/01/12 San Diego
Betting on Biotech to Catalyze U.S. Job Growth? Don’t Count On It 10/01/12 National
Bayer, Onyx Cancer Drug Wins FDA Approval Ahead of Schedule 09/27/12 San Francisco
Exelixis and Onyx Await Their Cancer-Drug Fates 09/18/12 San Francisco
Fearless Football and Biotech Picks For Fall 2012 09/04/12 National
Regulus Therapeutics Files for IPO as ‘Emerging Growth’ Company 08/20/12 San Diego
Kala, ImmunoGen, Boring Biotech, & More Boston Life Sciences News 07/13/12 Boston
Bristol-Myers Buys Amylin for $5.3B, Getting Diabetes Drugs 06/29/12 San Diego
Pfizer Takes on Genzyme With New Gaucher Drug 05/02/12 Boston
Genzyme, Epizyme, & Rib-X Among the Week’s Life Sciences Newsmakers 04/27/12 Boston
Cytokinetics Shows Hint of Effect With Drug for Lou Gehrig’s Disease 04/25/12 San Francisco
New Data on Genzyme MS Drug Shows Improvement in Disability 04/24/12 Boston
What Are the Hottest Targets in Biotech Today? 04/23/12 National
Xconomy Boston’s Top 20 Stories of Q1: Editor’s Picks 04/02/12 Boston
Biotech Can’t Sidestep Cost-Effectiveness Anymore 04/02/12 National
Third Rock’s Mark Levin: ‘Ultra-Super Positive’ on Biotech Innovation 03/29/12 Boston
Option to Buy: The New Face of Biotech Funding? 02/13/12 National
Biotech Is Raising More Cash, But Don’t Be Fooled: Startups are Hurting 01/23/12 National
Page 3 of 4 « previous page · next page »